Showing 1 - 13 results of 13 for search 'Marla C. Dubinsky', query time: 0.05s Refine Results
  1. 1
    Medical management of chronic pouch inflammation

    Medical management of chronic pouch inflammation by Maia Kayal, Marla C. Dubinsky

    Published 2022-01-01
    Get full text
    Article
  2. 2
    Iron Deficiency Is Common after Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis

    Iron Deficiency Is Common after Restorative Proctocolectomy with Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis by Ishaan Dharia, Taqwa Ahmed, Michael Plietz, Sergey Khaitov, Patricia Sylla, Alexander Greenstein, Marla C. Dubinsky, Maia Kayal

    Published 2023-07-01
    Get full text
    Article
  3. 3
    The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab

    The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab by Marla C. Dubinsky, Shervin Rabizadeh, John C. Panetta, Elizabeth A. Spencer, Annelie Everts-van der Wind, Thierry Dervieux

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis

    Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis by Marla C. Dubinsky, Mingyang Shan, Laure Delbecque, Trevor Lissoos, Theresa Hunter, Gale Harding, Larissa Stassek, David Andrae, James D. Lewis

    Published 2022-11-01
    Get full text
    Article
  5. 5
    Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults

    Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel u... by Marla C. Dubinsky, Peter M. Irving, Remo Panaccione, April N. Naegeli, Alison Potts-Bleakman, Vipin Arora, Mingyang Shan, Simon Travis

    Published 2022-04-01
    Get full text
    Article
  6. 6
    Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease

    Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease by Andres J. Yarur, Thierry Dervieux, Ryan Ungaro, Elizabeth A. Spencer, Alexandra Bruss, Lizbeth Nunez, Brandon Berens, Séverine Vermeire, Zhigang Wang, John C. Panetta, Erwin Dreesen, Marla C. Dubinsky

    Published 2025-02-01
    Get full text
    Article
  7. 7
    Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

    Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD by Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, Bruce E. Sands, John S. Hanson, David T. Rubin, Marla C. Dubinsky, Miguel Regueiro, Derek Gazis, Julie M. Crawford, Millie D. Long

    Published 2022-02-01
    Get full text
    Article
  8. 8
    Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis

    Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis by Brian G Feagan, Toshifumi Hibi, Vipul Jairath, Nathan Morris, Bruce E Sands, Marla C Dubinsky, Vipin Arora, April N Naegeli, Trevor Lissoos, Mingyang Shan, Jay Tuttle, Noah Agada

    Published 2023-12-01
    Get full text
    Article
  9. 9
    Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study

    Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIV... by Joana Torres, Geert R. D’Haens, Miguel Regueiro, Genoile Santana, Julian Panés, Séverine Vermeire, Sean Gardiner, Nicole Kulisek, Irene Modesto, Chinyu Su, Nervin Lawendy, Rajiv Mundayat, Jerome Paulissen, Marla C. Dubinsky

    Published 2025-02-01
    Get full text
    Article
  10. 10
    Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

    Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α by Elizabeth A. Spencer, Marla C. Dubinsky, Michael A. Kamm, Maria Chaparro, Paolo Gionchetti, Paolo Gionchetti, Fernando Rizzello, Fernando Rizzello, Javier P. Gisbert, Emily K. Wright, Julien D. Schulberg, Amy L. Hamilton, Dermot P. B. McGovern, Thierry Dervieux

    Published 2024-01-01
    Get full text
    Article
  11. 11
    Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α

    Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α by Elizabeth A. Spencer, Marla C. Dubinsky, Michael A. Kamm, Maria Chaparro, Paolo Gionchetti, Paolo Gionchetti, Fernando Rizzello, Fernando Rizzello, Javier P. Gisbert, Emily K. Wright, Julien D. Schulberg, Amy L. Hamilton, Dermot P. B. McGovern, Thierry Dervieux

    Published 2024-02-01
    Get full text
    Article
  12. 12
    Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis

    Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis by Xiang Guo, Peter M Irving, Laurent Peyrin-Biroulet, Séverine Vermeire, Joseph Wu, Irene Modesto, David T Rubin, Marla C Dubinsky, Andres J Yarur, Miguel Regueiro, Martina Goetsch, Krisztina Lazin, Guibao Gu, Aoibhinn McDonnell, Jesse Green, Alexis B Dalam

    Published 2025-01-01
    Get full text
    Article
  13. 13
    Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19

    Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19 by Graham J. Britton, Alice Chen-Liaw, Francesca Cossarini, Alexandra E. Livanos, Matthew P. Spindler, Tamar Plitt, Joseph Eggers, Ilaria Mogno, Ana S. Gonzalez-Reiche, Sophia Siu, Michael Tankelevich, Lauren Tal Grinspan, Rebekah E. Dixon, Divya Jha, Adriana van de Guchte, Zenab Khan, Gustavo Martinez-Delgado, Fatima Amanat, Daisy A. Hoagland, Benjamin R. tenOever, Marla C. Dubinsky, Miriam Merad, Harm van Bakel, Florian Krammer, Gerold Bongers, Saurabh Mehandru, Jeremiah J. Faith

    Published 2021-06-01
    Get full text
    Article

Search Tools: